MPMathieu Puyade

Mathieu Puyade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mathieu Puyade has a total of 407 co-authors. Here are the top co-authors by number of shared publications:

  • P. Roblot

    Service de médecine interne, Maladies infectieuses, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Faculté de médecine et pharmacie, Université de Poitiers, 6, rue de la Milétrie, 86000 Poitiers, France

    6 shared publications
  • Clément Beuvon

    Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Universitaire de Poitiers, France

    4 shared publications
  • Dominique Farge

    Internal Medicine Unit (04): CRMR MATHEC, Maladies Auto-immunes et Thérapie Cellulaire, Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France, AP-HP, St-Louis Hospital, INSERM UMR1342 (team ECSTRRA), IRSL, Paris-Cite University France, Paris, France

    4 shared publications
  • C. Landron

    Service de médecine interne, Maladies infectieuses, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France

    3 shared publications
  • Etienne Meriglier

    Service de médecine interne, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France

    3 shared publications
  • François Guilhot

    INSERM Clinical Investigation Centre 1402

    3 shared publications

Latest Publications

  • Traitement du syndrome des anti-synthétases

    by Jean-Philippe Martellosio, Mickaël Martin, Florent Broca, Van Minh Nguyen, Mathieu Puyade, Clément Beuvon

  • Parcours de soins des patients atteints d'hémopathies malignes en Poitou-Charentes

    by Mathieu Puyade

    La réduction des inégalités d'accès aux soins a toujours été un axe majeur des politiques de lutte contre le cancer. Alors qu'il existe de nombreuses études en cancérologie solide, peu d'études avec une méthodologie correcte existent en onco-hématologie, notamment chez les patients atteints de Myélome Multiple (MM). Cette maladie a vu son pronostic transformé par l'arrivée de nouvelles thérapeutiques dont l'usage a été rapidement intégré dans les recommandations de la Société Française d'Hématologie. L'objectif de travail intitulé Parcours de Soins des patients atteints d'hémopathie maligne en Poitou Charentes était donc de décrire et d'analyser les écarts aux recommandations, en prenant le MM comme premier exemple. Grâce au registre des Cancers Poitou-Charentes et à l'exhaustivité des cas qu'il assure, notre travail a permis de déterminer des variables associées à une inégalité d'accès aux soins. Ces variables sont démographiques (âge, distance entre le domicile et l'hôpital), liées à la tumeur (maladie symptomatique ou non), mais aussi organisationnelles (niveau de l'hôpital, passage en réunion de concertation pluridisciplinaire). De plus nous avons pu montrer que ces inégalités avaient un impact sur la survie globale des patients, notamment chez les plus âgés. Notre travail se poursuit par une analyse plus fine de la survie globale et l'étude des longs survivants du Myélome Multiple. A plus long terme, nous souhaitons appliquer cette approche à d'autres hémopathies.

  • Women's knowledge concerning the impact of chronic systemic diseases and related treatments on pregnancy

    by Marie Rolland, Odile Souchaud-Debouverie, Quentin Bodard, Aurélie Grados, Marie Pathé, Mathieu Puyade, Mickaël Martin

  • Top Cited Papers
    Open Access

    Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee

    by Tobias Alexander, Elisa Roldan, Nicoletta Del Papa, Dominique Farge, Jörg Henes, Zora Marjanovic, Mathieu Puyade, John A. Snowden, Julia Spierings, Jeska K. de Vries-Bouwstra, et al.

    Immune-mediated rheumatologic and musculoskeletal diseases (RMDs) comprise a heterogeneous group of systemic conditions that affect the connective tissues of the musculoskeletal system and internal organs. Immune-mediated RMDs are driven by chronic autoimmune responses and typically require continuous or repeated administration of immunosuppressive or biologic disease-modifying drugs. Although generally effective, these therapies can cause both short- and long-term side effects and may fail to control the disease with risk of irreversible tissue damage. For such patients, haematopoietic stem cell transplantation (HSCT) has been successfully employed over the past 30 years, but this procedure requires caution due to significant side effects. To address these aspects, updated recommendations for the use of HSCT in RMDs have been developed in collaboration with an international expert panel from the European Society for Blood and Marrow Transplantation (EBMT). The panel reviewed all available evidence regarding HSCT application since 2004. Based on this review, EBMT expert-based consensus recommendations were formulated to guide best practices and ensure high-quality patient care. These recommendations include detailed indications, contraindications, and cautionary notes specific to each RMD, along with comprehensive protocols for diagnostic work-up. They are intended to support clinicians, scientists, patients, and caregivers in the field of RMDs.


  • Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome

    by Tamim Alsuliman, Dimitri Psimaras, Nicolas Stocker, Simona Sestili, Anne Banet, Zoé Van de Wyngaert, Agnès Bonnin, Manuela Badoglio, Mathieu Puyade, Dominique Farge, et al.


  • Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)

    by Marie Jaïs, Pascal Roblot, François Maillot, Mohamed Hamidou, Antoine Enfrein, Alain Lescoat, Mathieu Puyade, Mickaël Martin, Amandine Perier

    Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. “Low dose” referred to patients receiving up to 7.5 mg of prednisone a day and “Very low dose” to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab. The secondary endpoint was a change in the proportion of patients with low or very low dose of prednisone as well as those without prednisone during the Belimumab course. Censoring occurred for patients who stopped Belimumab. Bivariate analyses were performed using the Wilcoxon signed-rank test. The threshold for statistical significance was set at p < 0.05. Thirty patients were included. All were female with a median age of 38 years. A significant reduction in prednisone dose was observed at month 6 (10 [7–20] vs 6.75 [2–9] mg, p < 0.0001), continued until month 12 (10 [7–20] mg vs 5 [0–7.12] mg, p < 0.001) and was sustained until month 24. The proportion of patients with very low dose of prednisone and those without prednisone progressively increased during the Belimumab course. Introducing Belimumab in patients with SLE, in real-life conditions, is associated with early and sustained corticosteroid-sparing effect.


  • Open Access

    French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases

    by D. Farge, G. Pugnet, M. Allez, C. Castilla-Llorente, E. Chatelus, P. Cintas, C. Faucher-Barbey, P. Labauge, C. Labeyrie, B. Lioure, et al.


  • Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients

    by Julien Rohmer, Yann Nguyen, Ludovic Trefond, Christian Agard, Jean Sebastien Allain, Alice Berezne, Pierre Charles, Pascal Cohen, Guillaume Gondran, Matthieu Groh, et al.


  • Open Access

    Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

    by Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, Candice Lesage, Jean-Marie Michot, Ariane Lappara, Stephane Ederhy, Eric Assenat, Maxime Faure, Nahema Issa, et al.

    Background Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecting any organ. Among these irAEs, myocarditis is rare but life-threatening. Methods We conducted a multicenter cross-sectional retrospective study with the aim of better characterizing ICI-related myocarditis. Myocarditis diagnosis was based on the recent consensus statement of the International Cardio-Oncology Society. Results Twenty-nine patients were identified, from six different referral centers. Most patients (55%) were treated using anti-programmed-death 1, rather than ICI combination (35%) or anti-programmed-death-ligand 1 (10%). Transthoracic echocardiography was abnormal in 52% of them, and cardiac magnetic resonance showed abnormal features in 14/24 patients (58%). Eleven patients (38%) were classified as severe. Compared with other patients, they had more frequently pre-existing systemic autoimmune disease (45% vs 6%, p=0.018), higher troponin level on admission (42-fold the upper limit vs 3.55-fold, p=0.001), and exhibited anti-acetylcholine receptor autoantibodies (p=0.001). Seven patients (24%) had myocarditis-related death, and eight more patients died from cancer progression during follow-up. Twenty-eight patients received glucocorticoids, 10 underwent plasma exchanges, 8 received intravenous immunoglobulins, and 5 other immunosuppressants. ICI rechallenge was performed in six patients, with only one myocarditis relapse. Discussion The management of ICI-related myocarditis may be challenging and requires a multidisciplinary approach. Prognostic features are herein described and may help to allow ICI rechallenge for some patients with smoldering presentation, after an accurate evaluation of benefit–risk balance.


  • Open Access

    Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database

    by Mickaël Martin, Hoan-My Nguyen, Clément Beuvon, Johana Bene, Pascale Palassin, Marina Atzenhoffer, Franck Rouby, Marion Sassier, Marie-Christine Pérault-Pochat, Pascal Roblot, et al.

    Immune checkpoint inhibitor (ICI)-related cytopenias have been poorly described. This study aimed to further characterize ICI-related cytopenias, using the French pharmacovigilance database. All grade ≥ 2 hematological adverse drug reactions involving at least one ICI coded as suspected or interacting drug according to the World Health Organization criteria and reported up to 31 March 2022, were extracted from the French pharmacovigilance database. Patients were included if they experienced ICI-related grade ≥ 2 cytopenia. We included 68 patients (75 ICI-related cytopenias). Sixty-three percent were male, and the median age was 63.0 years. Seven patients (10.3%) had a previous history of autoimmune disease. Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) were the most frequently reported (50.7% and 25.3%, respectively). The median time to onset of ICI-related cytopenias was 2 months. Nearly half were grade ≥ 4, and three patients died from bleeding complications of refractory ITP and from thromboembolic disease with active AIHA. Out of 61 evaluable responses, complete or partial remission was observed after conventional treatment in 72.1% of ICI-related cytopenias. Among the 10 patients with ICI resumption after grade ≥ 2 ICI-related cytopenia, three relapsed. ICI-related cytopenias are rare but potentially life-threatening. Further studies are needed to identify risk factors of ICI-related cytopenias.